XTAE
BARI
Market cap284mUSD
Jun 02, Last price
7,058.00ILS
Name
Panaxia Labs Israel Ltd
Chart & Performance
P/E
—
P/S
5,394.53
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-55.07%
Rev. gr., 5y
179.52%
Revenues
20m
-50.31%
Net income
-13m
L-69.02%
CFO
-563k
L-93.75%
Dividend
Jun 03, 2012107.388 ILS/sh
Profile
Panaxia Labs Israel Ltd provides pharmaceutical solutions for patients and physicians in Israel and internationally. It offers pharma-grade smokeless cannabis products, such as oral tablets, orodispersible tablets, sublingual tablets, oral oils, sublingual drops, solution for inhalation, pastilles, topicals, suppositories, and cannabis extracts in ethanol under the NAXIVA PANAXOL, NAXIVA-PANAXOL-ONKO, PANAXIR SENSE, PANAXIR, Axiban, Tikva, Ultra Health, and Salus brands. The company was incorporated in 2005 and is based in Lod, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 19,588 -50.31% | 39,419 -52.85% | ||||||
Cost of revenue | 35,612 | 68,652 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (16,024) | (29,233) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 322 | (327) | ||||||
Tax Rate | ||||||||
NOPAT | (16,346) | (28,906) | ||||||
Net income | (13,404) -69.02% | (43,270) 102.40% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 48 | |||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 15,505 | 28,353 | ||||||
Long-term debt | 20,881 | 11,935 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 36,105 | 37,491 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (563) | (9,008) | ||||||
CAPEX | (369) | |||||||
Cash from investing activities | 2,197 | (130) | ||||||
Cash from financing activities | (4,150) | 8,980 | ||||||
FCF | (20,117) | (13,556) | ||||||
| Balance | ||||||||
Cash | 281 | 2,797 | ||||||
Long term investments | ||||||||
Excess cash | 826 | |||||||
Stockholders' equity | (170,442) | (191,092) | ||||||
Invested Capital | 171,213 | 207,869 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 151 | |||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (12,871) | (22,131) | ||||||
EV/EBITDA | ||||||||
Interest | 3,113 | 2,226 | ||||||
Interest/NOPBT | ||||||||